The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.
about
Signaling Pathways in MelanogenesisCross-species models of human melanomaRAB7 counteracts PI3K-driven macropinocytosis activated at early stages of melanoma developmentUpdate on Molecular Pathology of Cutaneous Melanocytic Lesions: What is New in Diagnosis and Molecular Testing for Treatment?PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.Biology of advanced uveal melanoma and next steps for clinical therapeutics.Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions.Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cellsActivating MET kinase rearrangements in melanoma and Spitz tumours.A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERTMiR-21: an environmental driver of malignant melanoma?Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathwayPhosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma.Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapyPersonalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.Cross-talk between Dopachrome Tautomerase and Caveolin-1 Is Melanoma Cell Phenotype-specific and Potentially Involved in Tumor Progression.Metastatic risk and resistance to BRAF inhibitors in melanoma defined by selective allelic loss of ATG5.Melanoma Treatments: Advances and Mechanisms.What is a vertebrate pigment cell?Genetics of melanoma progression: the rise and fall of cell senescence.Developing strategies to predict photodynamic therapy outcome: the role of melanoma microenvironment.Sensitization of melanoma cells to temozolomide by overexpression of microRNA 203 through direct targeting of glutaminase-mediated glutamine metabolism.The impact of sequencing on diagnosis and treatment of malignant melanoma.Melanocytic nevi and melanoma: unraveling a complex relationship.SF3B1 and BAP1 mutations in blue nevus-like melanoma.Histone variants and melanoma: facts and hypotheses.Malignant melanoma of sun-protected sites: a review of clinical, histological, and molecular features.Tumour heterogeneity: principles and practical consequences.The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.Spitz nevi and Spitzoid melanomas: exome sequencing and comparison with conventional melanocytic nevi and melanomas.Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.Immunoplasticity in cutaneous melanoma: beyond pure morphology.p15 Expression Differentiates Nevus from Melanoma.Molecular genetic and immunotherapeutic targets in metastatic melanoma.Focus on cutaneous and uveal melanoma specificities.Genetically engineered mouse models of melanoma.De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival.The efficacy of anti-PD-1 agents in acral and mucosal melanoma.Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma.
P2860
Q26739678-2778319F-49B7-4CF4-BF5B-63E5DBD52746Q26782090-73D7E2BB-DBB4-470B-98C4-4312731FEB0FQ30657002-9071B3CB-F172-46E1-8B47-6B62CBFE92D0Q34928118-D8FECDB4-1ED3-48C1-8A8A-A8E52516EA94Q35060792-58D792D9-79DE-46DF-9469-33C2FD2CC052Q35079709-2B1BC8A5-55A7-4157-9C19-5454DDC0C5D0Q35433876-3962C8EF-B56D-465A-AF07-49A4F735BB17Q35530039-9DF8B3B8-BD16-44BA-BBE2-6C36A4E689BAQ35658282-84317A19-D5CE-4E26-96B0-9D2917D002E9Q35751775-319FD36E-A51C-4BA5-99C8-9F3D23273D95Q35786021-6E0582AF-04E7-4780-B56D-5E1F747CA3D5Q36109039-7942512C-8480-48F1-BF5D-A5ABFEE6C36BQ36750540-17B2D663-4BFB-47A9-9831-9ED0A4C3B21FQ36755569-FEB89CEE-55F7-4010-A1C2-2A53A229E8CAQ36759354-551D5AAB-A474-43C7-A3FA-54F0D983DFF8Q37066559-9AEDEE76-6A9B-4D70-ABA7-3A61BDBA7458Q37365473-48078EBE-8896-45E8-8871-982569FDAA06Q38433788-49F45078-7378-4F62-B92D-3A40A55A2229Q38561750-94A875DA-CEB3-48E0-9778-38AB07887904Q38589518-23A33D46-645D-4F49-B254-AF288C9F5348Q38595324-FDB92804-3B09-4D2C-8D3E-7274A4467583Q38700773-E29D7446-9E9A-4B9B-840D-688A0E330C02Q38715265-6843B622-AE8B-4C02-84E3-58F6F581B97DQ38730348-B345E504-27E3-4F02-B53C-DBE64E685B46Q38730428-BA149286-11D7-4967-9505-93D2AED48A37Q38748010-F98D14D6-D37E-4AB2-A29B-E8D05AC61207Q38769945-95D82FC3-2897-42EC-9502-6EF86CC918D3Q38842168-5477677F-1026-4099-8F08-090434E874EDQ38909389-6BA52382-4BAA-4178-887E-8A9F336DA1C5Q38967908-3E69CC31-2E85-47B4-82DF-0D8544B64846Q39031930-3A971C3A-5DC2-459F-B458-31DB290FBFA7Q39038191-A3CF61EE-2519-436A-A231-28D10637EDB4Q39067933-8E8B4FC6-A9F3-4036-B6FF-70EE0E5E06B0Q39180396-685CB38E-892D-4FD7-97AE-359B2F92FD66Q39208242-9EE99E83-9AA3-4316-B4FC-4ED618771680Q39312161-D20753A3-6B06-4DB4-92C3-E23F974DD45DQ39329577-C510CEB5-8C49-4342-8B78-BDF4135204ABQ39729548-02879CB3-6B91-41C0-A52A-CD0D9535E1D0Q40533419-BC1373D9-64A9-4011-B300-34579C3C6CAFQ40603999-8C81CAF2-13B1-45D3-B9BA-E848C56EB2A9
P2860
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.
@en
type
label
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.
@en
prefLabel
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.
@en
P2860
P1476
The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia.
@en
P2093
Boris C Bastian
P2860
P304
P356
10.1146/ANNUREV-PATHOL-012513-104658
P577
2014-01-01T00:00:00Z